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Purpose: To assess the 12-month efﬁcacy and safety proﬁle of an individualized regimen of ranibizumab
0.5 mg driven by stabilization criteria in patients with macular edema secondary to central retinal vein occlusion
(CRVO).
Design: A 24-month, prospective, open-label, single-arm, multicenter study.
Participants: Three hundred ﬁfty-seven patients.
Methods: Patients were treated with monthly ranibizumab 0.5-mg injections (minimum of 3 injections) until
stable visual acuity (VA) was maintained for 3 consecutive months. Thereafter, ranibizumab 0.5 mg was dosed as
needed if monthly monitoring indicated a loss of VA resulting from disease activity.
Main Outcome Measures: Mean change from baseline at month 12 in best-corrected VA (BCVA; primary
end point) and safety over 12 months. The efﬁcacy of this regimen in subgroups categorized by baseline BCVA
score, CRVO duration, or presence of macular ischemia (exploratory analysis).
Results: At baseline, the mean BCVA was 53.0 letters and mean CRVO duration was 8.9 months (median, 2.4
months). Ranibizumab 0.5-mg treatment resulted in a statistically signiﬁcant mean gain in BCVA from baseline at
month 12 of 12.3 letters (standard deviation [SD], 16.72 letters; P < 0.0001). The mean number of ranibizumab
injections up to month 12 was 8.1 (SD, 2.77). At month 12, mean BCVA gains were similar with or without macular
ischemia at baseline (11.6 vs. 12.1 letters); the mean BCVA gain was higher with baseline CRVO duration of less
than 3 months (13.4 letters) than with a longer duration (3e<9 months, 11.1 letters; 9 months, 10.9 letters).
Patients with lower baseline BCVA had larger mean BCVA gains at month 12 than those with higher baseline
BCVA (39/40e59/60 and 18.0/12.7/8.9 letters, respectively), although the absolute BCVA at month 12 was
higher with higher baseline BCVA. No new ocular or nonocular safety events were observed.
Conclusions: An individualized dosing regimen of ranibizumab 0.5 mg driven by stabilization criteria for up to
12 months resulted in signiﬁcant BCVA gain in a broad population of patients with macular edema secondary to
CRVO, including those with macular ischemia at baseline. The safety ﬁndings were consistent with those reported
in previous ranibizumab studies in patients with CRVO. Ophthalmology 2016;123:1101-1111 ª 2016 by the
American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Supplemental material is available at www.aaojournal.org.Central retinal vein occlusion (CRVO) is a common retinal
vascular disorder with a prevalence of approximately 1 per
1000 persons.1 Macular edema is a major complication in
CRVO that can lead to legal blindness.2e4 Intravitreal
antievascular endothelial growth factor (VEGF) agents
have proven efﬁcacy and are considered the ﬁrst-line treat-
ment option for macular edema secondary to CRVO.3,5e8
The results from the Central Retinal vein occlUsIon
Study: Evaluation of efﬁcacy and safety trial (CRUISE) 2016 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.study contributed signiﬁcantly in deﬁning anti-VEGF agents
as a treatment option for patients with macular edema sec-
ondary to CRVO. In the CRUISE study, 392 patients
received monthly injections of ranibizumab (0.3 or 0.5 mg)
or sham for the ﬁrst 6 months, followed by ranibizumab pro
re nata (PRN) treatment (based on prespeciﬁed criteria) for
the next 6 months. The improvements in best-corrected vi-
sual acuity (BCVA) and central foveal thickness observed
with a monthly dosing regimen of ranibizumab 0.5 mg in1101http://dx.doi.org/10.1016/j.ophtha.2016.01.011
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Ophthalmology Volume 123, Number 5, May 2016the ﬁrst 6 months were maintained with a PRN dosing
regimen until month 12.9,10
The CRUISE study results showed that 6 initial monthly
injections were successful in the treatment of patients with
macular edema secondary to CRVO. However, it is possible
that macular edema resulting from CRVO may resolve in
some patients without the need for monthly injections.2 In
the CRUISE study, during the PRN treatment period,
patients received a mean number of 3.3 injections, and
15% of patients did not require any treatment.
Furthermore, in the HORIZON-retinal vein occlusion
(HORIZON-RVO) trial (cohort II),11 an open-label exten-
sion of the CRUISE study,9 the need for retreatment in
patients with CRVO decreased to a mean of 3.5 injections
per year, although patients required more frequent follow-
ups than every 3 months.
The CRYSTAL study was designed to assess the long-
term efﬁcacy and safety of an individualized visual acuity
(VA) dosing regimen of ranibizumab 0.5 mg driven by
stabilization criteria. The CRYSTAL study was a 24-month
phase 3b, open-label, single-arm, multicenter study con-
ducted in a broad patient population with visual impairment
resulting from macular edema secondary to CRVO,
including those with macular ischemia or longer disease
duration. Herein, we report the efﬁcacy and safety results
from the ﬁrst 12 months of the CRYSTAL study.
Methods
Study Design
The CRYSTAL study was a 24-month phase 3b, open-label,
single-arm, multicenter study assessing the efﬁcacy and safety of
an individualized dosing regimen of ranibizumab 0.5 mg driven by
VA stabilization criteria in patients with visual impairment
resulting from macular edema secondary to CRVO. The study was
conducted at 86 sites across 18 countries worldwide (Appendix 2,
available at www.aaojournal.org). The study began in February
2012 and was completed in April 2015. The results of the ﬁrst
12 months of the CRYSTAL study were obtained in April 2014.
The CRYSTAL study was designed to assess the treatment
posology for CRVO according to the 2011 Lucentis European
Union Summary of Product Characteristics (EU SmPC)12 that
deviated from the posology of the pivotal CRUISE trial.9 A
sham arm was not used in the CRYSTAL study because the
superiority of ranibizumab treatment versus sham was established
in the CRUISE study. Laser could not be used as an active
comparator because it was shown to be ineffective in improving
VA in patients with macular edema secondary to CRVO in the
Central Vein Occlusion study.13 No other approved treatments
for macular edema secondary to CRVO were available at the
time of study initiation.
The study was conducted in accordance with the Declaration of
Helsinki and the protocol was reviewed and approved by the in-
dependent ethics committee or institutional review board for each
contributing center. Patients provided written informed consent
before entering the study. The study is registered with Clinical-
Trials.gov (identiﬁer, NCT01535261).
Patients
The study population consisted of patients 18 years of age or older
with visual impairment resulting from macular edema secondary to1102CRVO. The key inclusion criterion was a BCVA between 73 and
19 (inclusive) Early Treatment Diabetic Retinopathy Study
(ETDRS) letters (approximate Snellen equivalents, 20/40 and 20/
400, respectively) at screening and baseline.
The key exclusion criteria were use of intravitreal anti-VEGF
injections 3 months or less before baseline (either eye) and sys-
temic anti-VEGF agents 6 months or less before baseline, pan-
retinal laser photocoagulation 3 months or less before baseline,
focal or grid laser photocoagulation 4 months or less before
baseline, topical ocular or systemic corticosteroids administered for
30 consecutive days or more within 6 months before screening,
intraocular or periocular corticosteroid use 3 months or less before
screening (study eye), use of intraocular corticosteroid implants,
and the following conditions in either eye: active periocular or
ocular infection or inﬂammation at screening or baseline, uncon-
trolled glaucoma (intraocular pressure [IOP] 30 mmHg with
medication or according to the investigator’s judgment) at the time
of screening or baseline or diagnosis within 6 months before
baseline, and iris neovascularization or neovascular glaucoma.
Additional exclusion criteria are provided in Appendix 3 (available
at www.aaojournal.org).
Treatment
Administration of an intravitreal ranibizumab 0.5-mg injection was
as recommended in the EU SmPC.12 The treatment was initiated
with monthly consecutive intravitreal ranibizumab 0.5-mg in-
jections starting on day 1 (baseline). Per design, at least 3 initial
injections were required (baseline, month 1, month 2) until a stable
maximum VA (based on the investigator’s judgment) was observed
over 3 consecutive visits with treatment (months 1, 2, and 3; Fig 1,
available at www.aaojournal.org).
The investigators then monitored the patients for VA and dis-
ease activity on a monthly basis. Monthly ranibizumab 0.5-mg
injections were reinitiated if monitoring indicated a loss of VA
resulting from disease activity and were continued until VA sta-
bilization (deﬁned as 3 consecutive visits with stable VA [based on
investigator’s judgment], implying a minimum of 2 monthly in-
jections). Per protocol (and 2011 EU SmPC12), retreatment was
required upon observation of VA loss resulting from disease
activity (i.e., worsening of macular edema). Visual acuity loss
not accompanied by increased disease activity did not warrant
retreatment, and changes in retinal anatomic featuresdfor
example, on optical coherence tomography (OCT) imagesdnot
causing VA loss likewise did not warrant treatment. If VA did
not improve after the ﬁrst 3 mandatory injections, continued
treatment with ranibizumab was not recommended, and the
patient could receive alternative treatment at the investigator’s
discretion.
If both eyes were eligible for treatment, the study eye was
selected based on the investigators’ judgment. The nonstudy eye,
labeled the “fellow eye,” was allowed to receive ranibizumab
treatment within the study according to the local label, based on the
investigator’s judgment. However, both eyes were not treated with
ranibizumab on the same day, as recommended in the 2011 EU
SmPC.12
The use of rescue medication was not permitted. Panretinal
laser photocoagulation was permitted during the study in either
eye, but only later than month 3 in the study eye.
Study Objectives
The primary objective was to evaluate the efﬁcacy of an individ-
ualized dosing regimen of ranibizumab 0.5 mg driven by VA
stabilization criteria in patients with visual impairment resulting
from macular edema secondary to CRVO according to the 2011
Larsen et al  Individualized CRVO Stabilization by RanibizumabEU SmPC for ranibizumab. This was assessed by the mean change
in BCVA from baseline at month 12.
There were 2 secondary objectives. The ﬁrst was to evaluate the
efﬁcacy of an individualized dosing regimen of ranibizumab
0.5 mg driven by stabilization criteria as assessed by (1) the mean
average change in BCVA from baseline to month 1 through month
12 (i.e., the sum of each patient’s average BCVA changes from
month 1 through month 12 divided by the total number of patients,
compared with baseline, an expression for the area under the
change-in-BCVA curve); (2) the proportion of patients with a
BCVA improvement of 1 or more, 5 or more, 10 or more, 15 or
more, and 30 or more letters and loss of fewer than 15 letters from
baseline to month 12; (3) the proportion of patients attaining a
BCVA of 73 letters or more (approximate Snellen equivalent,
20/40) at month 12; and (4) the mean change in central reading
center (CRC)eassessed central subﬁeld thickness (CSFT) from
baseline to month 1 through month 12. The second was to assess
safety over 12 months. An exploratory objective of the study was
to evaluate the efﬁcacy of ranibizumab 0.5-mg treatment based on
baseline ocular characteristics such as presence of macular
ischemia, duration of CRVO, and BCVA scores.
Efﬁcacy Assessments
Study assessments were performed at screening, baseline (day 1),
and day 8 and at monthly visits.
Best-Corrected Visual Acuity. Best-corrected visual acuity
was assessed at every study visit by certiﬁed investigators or
designated staff using an ETDRS VA testing chart at an initial
testing distance of 4 m. If it was not possible to perform a sub-
jective refraction or VA testing at 4 m because VA was too poor for
the patient to read 4 letters or more on the ETDRS chart at this
distance, the refraction or VA testing was attempted at 1 m.
Optical Coherence Tomography. Optical coherence tomogra-
phy assessment was performed by certiﬁed operators at every visit
using spectral-domain OCT equipment, and the same machine was
used for assessment of the same patient throughout the study. The
investigator or the designated study staff evaluated the images
according to the standard practice and recorded the required vari-
ables in the clinical database. The images also were reviewed by a
CRC to ensure a standardized evaluation of CSFT (which is the
average retinal thickness of the circular area with a 1-mm diameter
around the foveal center), central foveal thickness, and the retinal
thickness at the foveal centerpoint and to capture the presence or
absence of qualitative parameters (i.e., intraretinal cystoid ﬂuid and
subretinal ﬂuid). Deﬁnitions of these quantitative and categorical
spectral-domain OCT parameters are provided in Appendix 4
(available at www.aaojournal.org). Image raw data were
evaluated using validated CRC software. The inner and outer
retinal boundaries were segmented at predeﬁned standardized
locations to ensure standardization across the spectral-domain
OCT instruments used. Quality control for the OCT grading pro-
cedure has been described previously.14
Fluorescein Angiography and Color Fundus Photo-
graphy. Fluorescein angiography, in conjunction with 7-ﬁeld color
fundus photography, was performed by certiﬁed operators at
screening, month 3, and month 12 (additional evaluation during the
other monthly visits was at the investigator’s discretion). The CRC
evaluated the images and captured the degree of ischemia at
baseline and during the study (Appendix 5, available at
www.aaojournal.org). Retinal ischemia was deﬁned by the extent
of retinal capillary loss (presence or absence of nonperfusion) in
the ETDRS grid center subﬁeld, as well as inner and outer
subﬁelds. We deﬁned macular ischemia as present if the CRC
scored capillary loss as mild, moderate, severe, or completely
destroyed in 1 or more location of the center, inner, or outersubﬁelds of the ETDRS grid. Here, we report the efﬁcacy results
for CRC-assessed macular ischemia. The CRC provided each
study site with an OCT manual as well as a retinal ﬂuorescein
angiography and photography manual, providing instructions and
guidance on how to capture and transfer images to ensure stan-
dardization across the sites. In case of loss of VA stabilization, the
investigators assessed all image methods to judge disease activity,
warranting retreatment.
Treatment Exposure. Information was collected on the number
of ranibizumab injections in the ﬁrst 12 visits, that is, baseline to
month 11.
Safety Assessments. Safety assessments comprised recording
of all adverse events (AEs) and serious AE (SAEs), with their type,
frequency, severity, and relationship to the study drug, ocular in-
jection procedure, or both, at all visits over the course of 12
months. Vital signs were measured and ophthalmic examination
was performed at each study visit.Statistical Analysis
The sample size calculation was based on the primary efﬁcacy end
point using the full analysis set (FAS) last observation carried
forward. The estimate of the standard deviation (SD) for the change
in BCVA from baseline to month 12 was based on the results from
the CRUISE study.9,10 The sample size was calculated using PASS
2002 sample size software (NCSS, LLC, Kaysville, UT).
Assuming an SD of 15.2 letters for the change (normally distrib-
uted) in BCVA from baseline at month 12, a sample size of 315
patients produced a 2-sided 95% conﬁdence interval equal to the
mean change in BCVA from baseline at month 12 of 1.7 letters.
Assuming a 10% dropout rate for the 12-month analysis, the ﬁnal
sample size was 350 patients. Unless otherwise speciﬁed, all 95%
conﬁdence intervals and P values were 2 sided and were based on
an a signiﬁcance level of 0.05.
All analyses were descriptive. The 95% conﬁdence intervals
and P values for the primary (related to the null hypothesis that this
mean change is equal to 0) and secondary efﬁcacy analyses
comparing response to baseline were calculated based on a t dis-
tribution/t test. The last observation carried forward approach was
used to impute missing variables. The CRC-assessed categorical
OCT parameters were summarized using the observed data for the
study eye in the FAS.
All efﬁcacy analyses were performed using the FAS, which
included all patients who received 1 or more administrations of
study treatment and had 1 or more postbaseline assessments for
BCVA in the study eye. Safety analyses were performed using the
safety set, which included all patients who received 1 or more
administrations of study treatment and had 1 or more postbaseline
safety assessments. All other analyses were performed using the
eligible set that comprised all patients who were deemed eligible to
receive the study treatment according to the investigator. The sta-
tistical analysis was performed using SAS software version 9.2
(SAS Institute, Inc., Cary, NC).Results
Patient Disposition and Baseline Characteristics
Three hundred ﬁfty-seven patients were enrolled, and 333 (93.3%)
completed the ﬁrst 12 months of the study. Treatment discontin-
uations were low, with no predominant reason for discontinuation.
The most common reasons for discontinuation were withdrawal of
consent (n ¼ 8 [2.2%]) and AEs (n ¼ 7 [2.0%]). The eligible set
and safety set included 357 patients, and the FAS included 3561103
Table 1. Baseline Demographics and Disease and Ocular
Characteristics (Eligible Set*)
Parameter
Ranibizumab 0.5 mg
(n [ 357)
Age (yrs), mean (SD) 65.5 (12.68)y
Gender, no. (%)
Male 229 (64.1)
Female 128 (35.9)
Predominant race, no. (%)
White 337 (94.4)
Black 4 (1.1)
Asian 5 (1.4)
Other 11 (3.1)
Study eye, no. (%)
Right 174 (48.7)
Left 183 (51.3)
Visual acuity (letters)
Mean (SD) 53.0 (15.00)
Median 55.0
Visual acuity stratiﬁcation group (letters), no. (%)
39 75 (21.0)
40e59 134 (37.5)
60 148 (41.5)
Duration of CRVO (mos)
Mean (SD) 8.9 (20.66)
Median 2.4
Duration of CRVO (mos), no. (%)
<3 193 (54.1)
3e<6 50 (14.0)
6e<9 26 (7.3)
9e<12 20 (5.6)
12 68 (19.0)
Intraocular pressure (mmHg), mean (SD) 15.7 (3.18)
Investigator-reported perfusion type, no. (%)
Ischemic 54 (15.1)
Nonischemic 300 (84.0)
Missing 3 (0.8)
CRC-assessed macular ischemia, no. (%) 107 (30.0)
CRC-assessed CSFT (mm), mean (SD) 692.8 (231.93)
CRC ¼ central reading center; CRVO ¼ central retinal vein occlusion;
CSFT ¼ central subﬁeld thickness; SD ¼ standard deviation.
Percentages are based on the total number of patients in the eligible set.
Baseline was deﬁned as the last available nonmissing value recorded just
before the start of treatment.
*Comprised all patients who were deemed to be eligible to receive study
treatment according to the investigator.
yn ¼ 355.
Ophthalmology Volume 123, Number 5, May 2016patients (1 patient was excluded from the FAS for not having 1 or
more postbaseline assessments).
At baseline, the mean age of the enrolled patients was 65.5
years (SD, 12.68 years), two-thirds were men (n ¼ 229 [64.1%]),
and most were white (n ¼ 337 [94.4%]; Table 1). The mean BCVA
at baseline was 53.0 letters (SD, 15.00 letters; Table 1).
Investigator-assessed ischemic perfusion type was present in 54
patients (15.1%) and CRC-assessed macular ischemia was present
in 107 patients (30.0%). In 138 patients (38.7%), macular ischemia
could not be assessed by the CRC, mainly because of severe
intraretinal hemorrhage. The mean duration of CRVO was 8.9
months (SD, 20.66 months), and the median duration was 2.4
months (quartile 1equartile 3, 0.9e8.7 months; Table 1).
The CRC-assessed mean CSFT at baseline was 692.8 mm (SD,
231.93 mm). The mean IOP at baseline was 15.7 mmHg (SD,
3.18 mmHg).1104Efﬁcacy
Best-Corrected Visual Acuity. At month 12, ranibizumab 0.5-mg
treatment resulted in a statistically signiﬁcant mean gain in BCVA
from baseline of 12.3 letters (SD, 16.72 letters; P < 0.0001; Fig 2).
Improvement in vision was observed to occur rapidly; at the ﬁrst
examination after the baseline injection (day 8), a mean gain in
BCVA from baseline of 8.9 letters (SD, 8.08 letters) was
observed (P < 0.0001; Fig 2). The mean average change in
BCVA from baseline to months 1 through 12 with ranibizumab
0.5-mg treatment was þ11.8 letters (SD, 12.44 letters; P < 0.0001).
With ranibizumab 0.5-mg treatment, 63.8% of patients (n ¼
227) gained 10 letters or more, 49.2% (n ¼ 175) gained 15 letters
or more, and 9.0% (n ¼ 32) gained 30 letters or more from baseline
at month 12. Most patients (94.1%; n ¼ 335) avoided loss of 15
letters or more from baseline at month 12. Approximately half of
the patients (47.5%; n ¼ 169) attained a BCVA score of 73 letters
or more (Snellen equivalent, 20/40) at month 12.
The exploratory analysis showed that treatment with ranibizu-
mab 0.5 mg resulted in BCVA gains from baseline at month 12
regardless of the baseline BCVA score, prior CRVO duration, or
presence of CRC-assessed macular ischemia at baseline. The mean
change in BCVA from baseline at month 12 was similar in patients
with macular ischemia at baseline (þ11.6 letters; SD, 14.92 letters)
or without it (þ12.1 letters; SD, 18.10 letters; Fig 3). The mean
change in BCVA from baseline at month 12 was higher in
patients with a lower baseline BCVA compared with those with
a higher baseline BCVA. The mean BCVA gain was 18.0 letters
in patients with a baseline BCVA of 39 letters or less, 12.7
letters in those with a baseline BCVA between 40 and 59 letters,
and 8.9 letters in those with a baseline BCVA of 60 letters or
more (Fig 4). However, patients with higher baseline BCVA had
a higher absolute BCVA at month 12 compared with those with
a lower baseline BCVA. The mean change in BCVA from
baseline at month 12 was higher in patients with a shorter
duration of CRVO at baseline compared with those with a longer
duration of CRVO at baseline. The mean BCVA gain was 13.4
letters in patients with a prior CRVO duration of less than 3
months, 11.1 letters in those with CRVO duration between 3 and
9 months, and 10.9 letters in those with CRVO duration of at
least 9 months (Fig 5).
Anatomic Outcomes. The mean CSFT decreased in a statisti-
cally signiﬁcant manner from baseline to month 12 with ranibi-
zumab 0.5 mg (693.7 mm [SD, 231.64 mm] vs. 358.0 mm [SD,
203.38 mm]; difference from baseline to month 12, 335.7 mm [SD,
285.02 mm]; P < 0.0001; Fig 6). Most of the reduction in CSFT
from baseline was reached by month 3 (361.5 mm [SD, 246.30
mm]), and the reduction was maintained up to month 12 (Fig 6).
With ranibizumab 0.5-mg treatment, there was an increase in the
proportion of patients with CSFT and central foveal thickness of
450 mm or less (predeﬁned cutoff value based on a subgroup
analysis of the CRUISE study) and a decrease in the proportion of
patients with visible intraretinal cystoid ﬂuid and subretinal ﬂuid
from baseline at month 12 (Table 2, available at
www.aaojournal.org).
Treatment Exposure. Patients received a mean of 8.1 ranibi-
zumab injections (SD, 2.77 injections; median, 9.0 injections) in
the study eye before month 12. Stable VA was achieved in 132
patients (37%) after the 3 initial mandatory injections, in 51 pa-
tients (14.3%) after 4 injections, in 23 patients (6.4%) after 5 in-
jections, and in 33 patients (9.2%) after 6 injections. During the
ﬁrst 12 monthly visits of the study, 35 patients (9.8%) received
only 3 injections, whereas 22 patients (6.2%) received the
maximum exposure of 12 injections (Fig 7). The mean number of
ranibizumab injections was similar in patients with macular
ischemia (7.5 [SD, 2.90]) and those without macular ischemia
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Figure 2. Graph showing mean change in best-corrected visual acuity (BCVA) from baseline to month 12 (full analysis set [last observation carried
forward]). *P < 0.0001 (related to the null hypothesis that this mean change is equal to 0) at month 12 versus baseline. All postbaseline comparisons for
individual time points up to month 12 versus baseline showed P < 0.0001. ETDRS ¼ Early Treatment Diabetic Retinopathy Study; SD ¼ standard
deviation; SE ¼ standard error of the mean.
Larsen et al  Individualized CRVO Stabilization by Ranibizumab(8.0 [SD, 2.88]). A total of 5 patients (1.4%) received treatment in
the fellow eye at any time during the 12 months, and 2 of the 5
patients (0.6%) had been treated already at baseline.
Safety
Serious Adverse Events up to Month 12. Ocular SAEs in the
study eye were reported in 8 patients (2.2%; Table 3, available atMean  (SD)
BCVA letters 
(absolute 
value) 
Baseline Day 8 Month 1 Month 2 Month 3 Month 4 Mon
Ischemia 54.5 (14.06)
61.9 
(15.99)
63.1 
(17.77)
64.8 
(17.32)
66.6 
(17.93)
64.9 
(17.81)
65
(18
No ischemia 55.5 (14.87)
66.3 
(15.77)
65.2 
(16.94)
67.3 
(18.02)
68.3 
(18.41)
67.4 
(18.95)
67
(19
Time
D8
0
5
10
15
20
25
0 2 4
Ischemia (n = 107)
M
ea
n
 
ch
an
ge
 (±
SE
) in
 B
CV
A
 
fro
m
 
ba
se
lin
e
to
 m
o
n
th
 1
2 
(E
TD
R
S 
le
tte
rs
) 
Figure 3. Graph showing mean change in best-corrected visual acuity (BCVA)
analysis set [last observation carried forward]). ETDRS ¼ Early Treatment Diabe
mean.www.aaojournal.org). Reduced VA was reported as an SAE in 2
patients (0.6%). All other ocular SAEs were reported in 1 patient
(0.3%) each. Retinal hemorrhage and retinal ischemia were
reported as SAEs in 1 patient each; both events were considered
by the investigator to be not related to the study treatment,
ocular injection, or both (Table 3, available at
www.aaojournal.org). Four SAEs reported in 2 patients were
suspected by the investigator to be related to the ocular injection:th 5 Month 6 Month 7 Month 8 Month 9 Month
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Figure 4. Graph showing mean change in best-corrected visual acuity (BCVA) from baseline to month 12 by baseline BCVA (full analysis set [last
observation carried forward]). ETDRS ¼ Early Treatment Diabetic Retinopathy Study; SD ¼ standard deviation; SE ¼ standard error of the mean.
Ophthalmology Volume 123, Number 5, May 2016hyphema, increased IOP, and vitreous hemorrhage (all severe and
reported in the same patient), and myopia (moderate severity and
reported in 1 patient). No action was taken because of hyphema
or myopia; paracentesis was performed once for increased IOP,
and concomitant treatment was given for increased IOP and
vitreous hemorrhage.Time (mo
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1106Nonocular SAEs were reported in 29 patients (8.1%; Table 3,
available at www.aaojournal.org). Anxiety, lower respiratory
tract infection, and pneumonia were reported in 2 patients (0.6%)
each. All other nonocular SAEs were reported in 1 patient
(0.3%) each. There was 1 case each of severe cardiac failure
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Larsen et al  Individualized CRVO Stabilization by Ranibizumabadministration) and severe cerebrovascular accident (resulting in
study drug discontinuation, hospitalization, and concomitant
medication administration); these 2 nonocular SAEs were
suspected by the investigator to be related to the study treatment.
Two patients died during the study: 1 of an unknown cause and
the other of causes secondary to gangrene of the foot (Table 3,
available at www.aaojournal.org). Both the deaths were
considered by the investigator to be not related to either the
study treatment or ocular injection.
Adverse Events up to Month 12. Ocular AEs in the study eye
were reported in 164 patients (45.9%; Table 4). Increased IOP (28
patients [7.8%]) and eye pain (19 patients [5.3%]) were the most
commonly reported ocular AEs (Table 4). Nonocular AEs were
reported in 190 patients (53.2%), of which nasopharyngitis was0.6 0.3 
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Figure 7. Bar graph showing ranibizumab treatment exposure during the
study (safety set, comprising all patients who had 1 or more safety assess-
ments after baseline and received 1 or more administrations of study
treatment). The total number of injections per patient was calculated and
the per-patient values are summarized. Injections at month 12 are not
included.most common (33 patients [9.2%]; Table 4). Overall, most
(>90%) of all reported ocular and nonocular AEs were mild or
moderate.
Overall, ocular AEs reported in 93 patients (26.1%) and non-
ocular AEs reported in 14 patients (3.9%) were suspected to be
related to the study treatment, ocular injections, or both (Table 5,
available at www.aaojournal.org). Increased IOP (25 patients
[7.0%]) and eye pain (patients 17 [4.8%]) were the most
commonly reported ocular AEs suspected to be related to the
study treatment, ocular injection, or both. Headache (7 patients
[2.0%]) was the most commonly reported nonocular AE
suspected to be related to the study treatment, ocular injection, or
both.
Ocular and nonocular AEs leading to study treatment discon-
tinuation are shown in Table 6 (available at www.aaojournal.org).
Five ocular AEs reported in 2 patients (0.6%) resulted in study
treatment discontinuation; none were suspected by the
investigator to be related to the study treatment, ocular injection,
or both. Eight nonocular AEs reported in 8 patients (2.2%)
resulted in study treatment discontinuation; of these AEs, 2 (the
SAE of cerebrovascular accident mentioned above and transient
ischemic attack) were suspected by the investigator to be related
to the study treatment, ocular injection, or both.Discussion
The CRYSTAL study evaluated an individualized dosing
regimen of ranibizumab 0.5 mg driven by VA stabilization
criteria in patients with visual impairment resulting from
macular edema secondary to CRVO. This study showed that
treatment of CRVO with ranibizumab according to the 2011
EU SmPC leads to VA gains versus baseline at all time
points from day 8 (the ﬁrst examination after ranibizumab
0.5-mg injection at baseline) to month 12. At month 12,
approximately half of the patients attained a BCVA of 731107
Table 4. Ocular (Study Eye) and Nonocular Adverse Events
Regardless of Study Drug Relationship Reported in 2% or More of
Patients (Safety Set*)
Preferred Term Ranibizumab 0.5 mg (n [ 357)
Ocular AEs, total 164 (45.9)
Intraocular pressure increased 28 (7.8)
Eye pain 19 (5.3)
Ocular hypertension 18 (5.0)
Macular edema 15 (4.2)
Conjunctival hemorrhage 14 (3.9)
Vitreous ﬂoaters 14 (3.9)
Dry eye 11 (3.1)
Macular ﬁbrosis 11 (3.1)
Visual acuity reduced 12 (3.4)
Cataract 9 (2.5)
Vision blurred 11 (3.1)
Injection site pain 10 (2.8)
Vitreous detachment 7 (2.0)
Ocular discomfort 8 (2.2)
Blepharitis 8 (2.2)
Nonocular AEs, total 190 (53.2)
Nasopharyngitis 33 (9.2)
Inﬂuenza 8 (2.2)
Back pain 8 (2.2)
Headache 15 (4.2)
Hypertension 29 (8.1)
Dizziness 7 (2.0)
Diarrhea 7 (2.0)
Lower respiratory tract infection 7 (2.0)
AE ¼ adverse event.
Data are no. (%). The values in bold are the total number (%) of ocular
and nonocular AEs reported during the study Preferred terms are sorted in
descending frequency. A patient with multiple occurrences of an AE under
1 treatment is counted only once in the AE category for that treatment. A
patient with multiple AEs within the primary system organ class (eye dis-
orders) is counted only once in the total row. Adverse events were coded
using the Medical Dictionary for Regulatory Activities (MedDRA) version
17.1.
*Comprised all patients who had 1 or more safety assessments after baseline
and received 1 or more administrations of study treatment.
Ophthalmology Volume 123, Number 5, May 2016letters or more (Snellen equivalent, 20/40), and there was a
statistically signiﬁcant reduction in mean CSFT from
baseline.
The numerical difference in mean BCVA gain at month
12 between the CRYSTAL and CRUISE studies (CRYS-
TAL, 12.3 letters vs. CRUISE, 13.9 letters10; Fig 8,
available at www.aaojournal.org) could be related to
differences in baseline characteristics. The demographics
(e.g., male-to-female ratio) and baseline characteristics of
patients included in the CRYSTAL study are more repre-
sentative of those with CRVO in the general population.15,16
In the CRYSTAL study, patients had a higher mean BCVA
score than in CRUISE (53.0 vs. 48.1 letters). Patients in the
CRYSTAL study also had a longer prior duration of CRVO
compared with patients in the CRUISE study (8.9 vs. 3.3
months in the ranibizumab 0.5-mg arm). Both baseline
BCVA and timely treatment initiation were shown to be
important predictors of VA gain at later time points in
ranibizumab studies in the context of retinal vein occlusion
and other indications.9,17e24 Consistent with these1108observations, the exploratory subgroup analysis in the
CRYSTAL study showed that the BCVA gain with ranibi-
zumab 0.5 mg was higher in patients with a lower baseline
BCVA score compared with those with a higher baseline
BCVA score. It was also higher in patients with a shorter
duration of CRVO at baseline than those with a longer
duration (although the mean gains with ranibizumab 0.5 mg
were still >10 letters in patients with a CRVO duration of
9 months), stressing the need for early treatment initiation.
The effect of delayed treatment initiation also was observed
previously in the CRUISE study among patients initially
randomized to sham who received ranibizumab 0.5 mg after
6 months. In these patients, although overall improvement
in BCVA was observed at month 12, the gain was signiﬁ-
cantly lower than that observed in patients receiving rani-
bizumab throughout the study.10 A VA loss of 15 letters or
more at month 12 was reported in a higher percentage
(5.9%) of patients in the CRYSTAL study than in the
CRUISE study (2.3%),10 possibly related to the
differences in the patient population. A VA loss of 15
letters or more was reported in a similar percentage
(5.3%) of patients receiving aﬂibercept at week 52 in the
COPERNICUS study, which included patients with retinal
nonperfusion at baseline.25
Moreover, in the CRYSTAL study, at least in some pa-
tients, withdrawal of initial monthly treatments and switch
to an individualized dosing regimen driven by VA stabili-
zation criteria may have occurred too early, because the
stability and retreatment criteria were based on VA loss as a
consequence of disease activity. Retreatment could not be
applied when CSFT remained abnormal or increased but
VA was still unchanged (as recommended in the 2011
EU SmPC).12 The numerical difference in BCVA gain, in
addition to the lower CSFT response observed in the
CRYSTAL study compared with the CRUISE study (in
which both VA and OCT were considered as retreatment
criteria),9,10 highlighted the need to make retreatment de-
cisions on the basis of OCT ﬁndings and VA changes. The
ranibizumab EU SmPC, modiﬁed in 2014,26 recommends
anatomic parameters as well as VA stabilization to guide
treatment decisions by physicians.
Overall, the efﬁcacy results from the CRYSTAL study
add to the existing data from other ranibizumab studies in
patients with macular edema secondary to CRVO. The
HORIZON-RVO11 and bRanch rETinal vein occlusion or
centrAl retinal veIn occlusioN-retinal vein occlusion
(RETAIN-RVO)27 (an open-label extension study that
included patients who completed HORIZON-RVO [cohort
II]11) studies showed that VA gains were sustained up to 48
months with ranibizumab 0.5-mg PRN dosing. The SHORE
study,28 which assessed monthly versus PRN dosing of
ranibizumab 0.5 mg, showed similar BCVA gains with 2
dosing regimens at month 15 in patients with macular
edema secondary to CRVO. The COMRADE-C study, the
ﬁrst head-to-head study that compared the efﬁcacy and
safety of ranibizumab PRN versus dexamethasone implant,
showed the superior efﬁcacy of ranibizumab compared with
dexamethasone in patients with CRVO, and the treatment
schedule in COMRADE-C was similar to that of the
CRYSTAL study. The positive results from all of these
Larsen et al  Individualized CRVO Stabilization by Ranibizumabstudies validate the beneﬁts of ﬂexible ranibizumab 0.5-mg
therapy in patients with CRVO.
The mean number of injections during the 12-month
period in the CRYSTAL study (8.1; 3 initial mandatory
injections until stable VA was achieved and sustained over 3
consecutive monthly assessments) was similar to the mean
number of injections during the 12-month period in the
CRUISE study (7.9; 6 initial mandatory injections). The
mean number of injections decreased with continued rani-
bizumab treatment in other studies: 4.7 during an average of
18.2 months of follow-up in the HORIZON study and 4.1
and 2.5 in the ﬁrst and second year, respectively, of the
RETAIN study.27 However, it should be noted that in the
RETAIN study, 56% of patients still required an average
of 6 injections during the last year of follow-up, and
slightly more than half of the patients showed VA loss,
suggesting a guarded prognosis in these patients; patients
without edema resolution in general were older and had
hypertension and possibly retinal ischemia that could have
caused a positive feedback loop promoting chronicity
resulting from high levels of VEGF.27 In the CRYSTAL
study, during the 12-month period, the mean number of
ranibizumab injections was similar in patients with or
without macular ischemia, although the study was not
powered to detect a difference.
Similar sustained efﬁcacy with an individualized, as-
needed regimen also has been reported with other anti-
VEGF agents. In the COPERNICUS and GALILEO
studies, VA gains achieved with 6 monthly aﬂibercept in-
jections largely were maintained up to 1 year with PRN
injections.25,29 However, in the COPERNICUS study, the
visual and anatomic gains decreased during the second year
with PRN dosing and during quarterly evaluations, sug-
gesting that more frequent monitoring may be necessary to
prevent disease recurrence.30 Because monthly monitoring
was used in the ﬁrst 12 months of the CRYSTAL study,
an important observation from this study may be that
regular monitoring plays an essential role in achieving
successful outcomes from individualized dosing. The next
12 months of the CRYSTAL study will assess the
feasibility of bimonthly monitoring in patients with
stable VA.
The visual prognosis is reported generally to be poorer
in CRVO eyes with macular ischemia than in nonischemic
eyes.2,31 In the exploratory analysis in the CRYSTAL
study, the BCVA gains with ranibizumab 0.5 mg were
similar in patients with CRC-assessed macular ischemia
and those without. Similarly, in the COPERNICUS and
GALILEO studies, efﬁcacy with PRN aﬂibercept was
comparable in patients with or without retinal non-
perfusion.25,29 In addition, a 6-month interventional case
series with bevacizumab showed that mean VA gains at 6
months were similar in patients with or without macular
ischemia.32 These results suggest anti-VEGF agents to be
effective in CRVO patients with retinal ischemia. In the
CRYSTAL study, the difference in the proportion of pa-
tients at baseline with CRC-assessed macular ischemia or
investigator-assessed ischemic perfusion type could be
related to the individual assessment method used, and this
needs to be investigated in future studies. Visual outcomeswere similar between patients with or without macular
ischemia at baseline. Further information on the impact of
the severity (rather than just the presence or absence) of
ischemia on VA would be valuable; indeed, these analyses
have been performed and will form the basis of a separate
publication.
Safety results in the CRYSTAL study were consistent
with the well-established safety proﬁle of ranibizumab in
patients with CRVO.9e11,27 No new or unexpected AEs
were reported during the study. Anti-VEGF therapy, when
compared with lack of treatment, was reported to reduce the
odds of progression of iris neovascularization and associated
neovascular glaucoma, 2 recognized complications of un-
treated CRVO.3 The few AEs of iris neovascularization or
neovascular glaucoma reported in this and other anti-
VEGF studies10,29 suggest that these AEs, although rare,
can occur despite anti-VEGF therapy.
The study had several limitations. It was open label and
lacked a control group. Leaving the selection of the study
eye to the discretion of the investigator could result in a
potential bias toward selection of the eye most likely to
beneﬁt from treatment. However, the low percentage of
patients (0.6%) who received bilateral treatment at baseline
in this study renders any such bias inﬂuencing the overall
study outcomes unlikely. The number of letters signifying
loss of VA activity was not deﬁned, but based on the in-
vestigator’s judgment. This was based on the recommen-
dations provided in the EU SmPC at that time, which were
to be tested here.12 Also, the investigators were not masked
to the CSFT ﬁndings, although per protocol, retreatment
could not be based on abnormal CSFT ﬁndings if VA was
stable. Finally, the analysis of ranibizumab efﬁcacy in the
subgroups based on baseline ischemia, CRVO duration, or
BCVA score was exploratory, and the analysis based on
baseline ischemia focused only on macular ischemia,
regardless of baseline ischemia severity.
In conclusion, the individualized dosing regimen of
ranibizumab 0.5 mg driven by VA stabilization criteria (3
mandatory injections followed by dosing as needed) for 12
months resulted in statistically signiﬁcant BCVA gains in
patients with macular edema secondary to CRVO. The
BCVA gains were observed in a broad population of pa-
tients, including those with macular ischemia at baseline.
Overall, ranibizumab 0.5 mg up to 12 months was generally
well tolerated in this patient population. No new or unex-
pected ocular or nonocular safety events were identiﬁed.References
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Ophthalmology Annual Meeting, May 2015, Denver, Colorado; and 30th
Asia-Paciﬁc Academy of Ophthalmology Congress, April 2015, Guangz-
hou, China.
*Members of the CRYSTAL Study Group are listed in Appendix 1
(available at www.aaojournal.org).
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VEGF ¼ vascular endothelial growth factor.
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